A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Trial details
- Registry ID
- NCT06092034
- Drugs studied
- RP-A501
TrialRedline tracks 4 clinical trials sponsored by Rocket Pharmaceuticals Inc.: 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Gene Therapy Study of RP-A501 in Male Patients With Danon DiseaseNCT06092034 | RP-A501 | Recruiting | 2028-06Estimated |
| Gene Therapy for Fanconi Anemia, Complementation Group ANCT04248439 | RP-L102 | Active not recruiting | 2026-05-05Estimated |
| Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase DeficiencyNCT06422351 | RP-L301 | Suspended | 2029-01Estimated |
| Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype ANCT04069533 | RP-L102 | Unknown | 2025-02Estimated |
Names as written in the registry records.
NCT06092034 · Rocket Pharmaceuticals Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Evaluation of efficacy via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index Description: Increase of myocardial tissue expression of LAMP2 protein and decrease in left ventricular mass index (LVMI). Time frame: 12 Months post-infusion. After: Measure: Evaluation of Efficacy: Improvement as assessed via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index (LVMI) Description: Myocardial tissue expression of LAMP2 protein improved from baseline to ≥ Grade 1 (by IHC), AND, ≥ 10% decrease in LVMI from baseline. Time frame: 12 months post-infusion.
Before: 14 participants (planned). After: 18 participants (planned).
Before: Apr 2028. After: Jun 2028.
NCT06422351 · Rocket Pharmaceuticals Inc.
Before: Nov 2026. After: Jan 2029.
Before: Not yet recruiting. After: Suspended.
NCT04248439 · Rocket Pharmaceuticals Inc.
Before: May 2026. After: 5 May 2026.